Does the VA Risk Analysis Index Overestimate Frailty in Patients with Localized Prostate Cancer? [0.03%]
退伍军人事务局风险分析指数是否高估了局部前列腺癌患者的身体衰弱状况？
Pranay Manda,Siddharth Marthi,Ernest Morton et al.
Pranay Manda et al.
Introduction and objectives: The Veterans Affairs (VA) Health System recently implemented the Risk Analysis Index (RAI) to assess frailty prior to surgery. Elevated RAI scores trigger a "surgical pause" and geriatric cons...
Is Lower Pole Access Safer for Ultrasound-Guided Supine Percutaneous Nephrolithotomy? [0.03%]
仰卧经皮肾镜取石术超声引导下较低的穿刺点更安全吗？
Ziv Savin,Linda Dayan Rahmani,Eve Frangopoulos et al.
Ziv Savin et al.
Introduction: Ultrasound (US) guided supine percutaneous nephrolithotomy (PCNL) is increasingly being adopted. The aim of this study is to assess the safety and efficacy of lower versus non-lower pole access in supine US-...
Utility of 18F-Flotufolastat PET/CT Imaging in High-Risk Prostate Cancer in a Real-World Setting [0.03%]
18F-氟托菲帕肽 PET/CT 成像在真实世界高危前列腺癌中的应用价值
Zachariah Taylor,Kayla Meyer,Nachum Stollman et al.
Zachariah Taylor et al.
Introduction: This investigator-initiated, prospective low-intervention phase 3 study evaluated the clinical utility of PSMA PET/CT imaging with 18F-flotufolastat (formerly 18F-rhPSMA-7.3) in men with newly diagnosed high...
Editorial Commentary [0.03%]
述评
Samuel H Eaton
Samuel H Eaton
Editorial Commentary [0.03%]
述评
Richard J Boxer
Richard J Boxer
Authentic or Algorithm? Assessing the Use of Generative AI in Urology Residency Personal Statements [0.03%]
真实还是算法？评估生成式AI在泌尿学住院医师个人陈述中的应用
Jay R Dalvi,Andrew J Zganjar,Anna E Witten et al.
Jay R Dalvi et al.
Histologic Patterns and Germline Genetic Testing Outcomes in Presumed Sporadic Bilateral Renal Masses [0.03%]
疑似散发性双侧肾脏肿瘤的组织病理模式和遗传咨询结果
Kieran Lewis,Jason M Scovell,Eran N Maina et al.
Kieran Lewis et al.
Introduction: Bilateral renal masses (BRM) are classically linked to inherited familial syndromes, often associated with distinct histologies. Current guidelines recommend genetic counseling for all BRM patients, however ...
The Who and What of Testosterone Replacement Therapy: Trends in Medicare Part D Testosterone Claims [0.03%]
美国医疗保险D部分睾酮处方的供需变化趋势（2007-2013）
Leane Kuo,Michael Sessine,Lillian Lai et al.
Leane Kuo et al.
Editorial Commentary [0.03%]
述评
David-Dan Nguyen,Girish S Kulkarni,Laura C Rosella et al.
David-Dan Nguyen et al.
Reply by Authors [0.03%]
作者回复
Yool Ko,Dhiraj S Bal,Premal Patel
Yool Ko